UCB To Jump-Start Ongoing Lupus Studies For Immunomedics’ Epratuzumab
This article was originally published in The Pink Sheet Daily
Executive Summary
UCB licenses rights to epratuzumab for all autoimmune disease indications for roughly $208 mil. plus royalties.